| |
As evidence amounts that it is now a progressive condition, the understanding of heart failure, a condition often treated only for its bothersome symptoms, is being transformed. The move towards treating “high risk” patients who currently have mild or no symptoms expects to expand the market revenue for pharmaceutical market participants.
New analysis from Frost & Sullivan reveals that the U.S. Heart Failure Emerging Markets earned revenue of $1.33 billion in 2004 and estimates to reach $4.13 billion in 2011.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Heart Failure Emerging Markets, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
“Followed by landmark trials evaluating the efficacy of a new medication, as part of an already complex drug regimen, the current model of heart failure drug development is not likely to be sustained indefinitely,” notes Frost & Sullivan Research Analyst Linda Liu. “Critical factors that contribute to patient’s treatment with every possible beneficial drug are the lack of comparative clinical trials and the ability to develop a personalized drug regimen for patients.”
With issues still surrounding comparability between different therapeutic classes, such as ACE inhibitors and beta-blockers, and ACE inhibitors and ARBs, there is no significant progress in streamlining the drug regimen. In addition, with multiple novel products in the pipeline, deciphering which products should be part of the standard drug regimen is something that needs addressing, not only in practice but also in large-scale clinical trials.
In the U.S. heart failure market, landmark studies are changing the management of heart failure and expect to play an increasing role in guiding treatment and competition in this market. Physicians are currently changing their treatment practices in response to long-term studies such as VALIANT.
“Competitors are investing heavily in such trials, which take on average four to seven years and this is becoming more and more of an order qualifier in this market,” notes Liu. “This expects to put barriers in place for small companies that do not have the resources to invest in such costly trials.”
Small pharmaceutical companies who are positioned to enter the market are encouraged to enter into marketing and development partnerships with large pharmaceutical companies in order to leverage the financial resources needed to achieve success in the heart failure market.
U.S. Heart Failure Markets, a part of the Pharmaceuticals Subscription (9611), provides an overview and outlook for the market. This research includes detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
|
melina.trevino[.]frost.com 
